(Q84780336)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

editorial

0 references

title

Antiangiogenic therapy accelerates tumor metastasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

main subject

angiogenesis inhibitor

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20727589

20 June 2024

author name string

Domenico Ribatti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20727589

20 June 2024

publication date

19 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

11 February 2020

https://api.elsevier.com/content/article/PII:S0145212610003814?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

https://api.elsevier.com/content/article/PII:S0145212610003814?httpAccept=text/plain

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

20 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

24-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

Tumor angiogenesis: therapeutic implications

11 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

20 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

20 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

20 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

20 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

20 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

20 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Comparing antibody and small-molecule therapies for cancer

20 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

20 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

20 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

20 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

20 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

20 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

20 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

20 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

20 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

20 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

20 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.

20 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View

20 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Pericytes limit tumor cell metastasis

20 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

20 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

20 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis

20 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma

20 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.

20 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

20 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

20 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.LEUKRES.2010.07.038

20 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20727589%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference